论文部分内容阅读
目的观察恩替卡韦联合腹水浓缩回输应用于乙肝肝硬化腹水的临床效果。方法 68例乙肝肝硬化腹水患者,随机分为对照组与研究组,每组34例。对照组予腹水浓缩回输,研究组予恩替卡韦联合腹水浓缩回输,分析两组患者治疗期间相关情况。结果研究组HBV-DNA(乙肝病毒基因)、ALT(谷氨酸转氨酶)水平明显低于对照组,比较差异具有统计学意义(P<0.05);研究组腹围、体重改善效果明显优于对照组,比较差异具有统计学意义(P<0.05)。结论乙肝肝硬化腹水行恩替卡韦联合腹水浓缩回输治疗效果显著,能有效降低患者HBV-DNA水平。
Objective To observe the clinical effect of entecavir combined with ascites concentration and transfusion in the treatment of ascites caused by hepatitis B cirrhosis. Methods 68 cases of hepatitis B cirrhosis patients were randomly divided into control group and study group, 34 cases in each group. In the control group, the ascites was concentrated and transfused, and the study group was given entecavir combined with ascites for concentration and reinfusion, and the related situation of the two groups was analyzed. Results The levels of HBV-DNA (hepatitis B virus) and ALT (glutamic-pyruvic transaminase) in the study group were significantly lower than those in the control group (P <0.05). The abdominal circumference and body weight of the study group were significantly better than those of the control group Group, the difference was statistically significant (P <0.05). Conclusion Hepatitis B cirrhosis astigmatism with entecavir combined with transfusion of ascites results in significant therapeutic effect, can effectively reduce the level of HBV-DNA in patients.